TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia

Annals of the New York Academy of Sciences

Volumn 1266, Issue 1, 2012, Pages 118-123

  Kikushige, Yoshikane ^a   Akashi, Koichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

AML; Leukemic stem cell; TIM 3

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G2A ANTIBODY; T CELL IMMUNOGLOBULINMUCIN 3; THY 1 ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 84865369927     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06550.x     Document Type: Article

References (32)

1. Lapidot, T. et al 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
2. Bonnet, D. & J.E. Dick 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3: 730-737.
3. Hope, K.J., L. Jin & J.E. Dick 2004. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5: 738-743.
4. Taussig, D.C. et al 2008. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568-575.
5. Martelli, M.P. et al 2010. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 116: 3907-3922.
6. Taussig, D.C. et al 2010. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115: 1976-1984.
7. Ishikawa, F. et al 2007. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25: 1315-1321.
8. Bhatia, M. et al 1997. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. USA 94: 5320-5325.
9. Ishikawa, F. et al 2005. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106: 1565-1573.
10. Krause, D.S. & R.A. Van Etten 2007. Right on target: eradicating leukemic stem cells. Trends Mol. Med. 13: 470-481.
11. Kikushige, Y. et al 2010. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 7: 708-717.
12. Jan, M. et al 2011. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc. Natl. Acad. Sci. USA 108: 5009-5014.
13. Monney, L. et al 2002. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541.
14. Sanchez-Fueyo, A. et al 2003. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 4: 1093-1101.
15. Sabatos, C.A. et al 2003. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 4: 1102-1110.
16. Zhu, C. et al 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6: 1245-1252.
17. Anderson, A.C. et al 2007. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318: 1141-1143.
18. Nakayama, M. et al 2009. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113: 3821-3830.
19. Nakae, S. et al 2007. TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood 110: 2565-2568.
20. Dekruyff, R.H. et al 2010. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 184: 1918-1930.
21. Nimmerjahn, F. & J.V. Ravetch 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19: 239-245.
22. Nimmerjahn, F. & J.V. Ravetch 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
23. Uchida, J. et al 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
24. Saito, Y. et al 2010. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2: 17ra19.
25. Jin, L. et al 2006. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12: 1167-1174.
26. Majeti, R. et al 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299.
27. Taussig, D.C. et al 2005. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092.
28. van Rhenen, A. et al 2007. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110: 2659-2666.
29. Aikawa, Y. et al PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat. Med. 16: 580-585, 581p following 585.
30. Hosen, N. et al 2007. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 104: 11008-11013.
31. Bakker, A.B. et al 2004. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 64: 8443-8450.
32. Wang, P.L. et al 1992. Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily. J Immunol. 148: 2600-2608.